伏环孢素长期治疗狼疮肾炎的安全性与疗效:3期AURORA 2临床试验
AURORA 2研究评估伏环孢素对比安慰剂在狼疮肾炎患者中额外治疗两年的长期安全性、耐受性和疗效。216例患者入组,治疗耐受良好,86.1%完成研究,无意外安全信号;伏环孢素组完全肾脏缓解率50.9% vs 对照组39.0%(OR 1.74,95%CI 1.00-3.03)。
要点
- 伏环孢素组与对照组不良事件发生率分别为86%和80%,不良事件谱与AURORA 1相似但频率降低。
- 研究者报告肾小球滤过率下降和高血压不良事件在伏环孢素组更常见(分别为10.3% vs 5.0%和8.6% vs 7.0%)。
- 两年eGFR斜率伏环孢素组为-0.2 mL/min/1.73 m2(95%CI -3.0至2.7),对照组为-5.4 mL/min/1.73 m2(95%CI -8.4至-2.3)。
核心结论
- 数据表明伏环孢素在狼疮肾炎患者中随访三年的长期治疗具有安全性和疗效。
研究设计与样本
- AURORA 2为3期临床试验,评估完成一年AURORA 1研究后额外两年伏环孢素对比安慰剂治疗的安全性和疗效。
- 患者继续AURORA 1中随机分配的双盲伏环孢素或安慰剂治疗,联合霉酚酸酯和低剂量糖皮质激素。
- 共216例患者入组AURORA 2。
主要发现
- 治疗耐受良好,86.1%完成研究,无意外安全信号。
- 不良事件在伏环孢素组和对照组发生率分别为86%和80%,不良事件谱与AURORA 1相似但频率降低。
- 研究者报告肾小球滤过率下降不良事件伏环孢素组10.3% vs 对照组5.0%,高血压不良事件伏环孢素组8.6% vs 对照组7.0%。
- 平均校正估算肾小球滤过率在两组均处于正常范围且稳定。
- 两年eGFR斜率伏环孢素组为-0.2 mL/min/1.73 m2(95%CI -3.0至2.7),对照组为-5.4 mL/min/1.73 m2(95%CI -8.4至-2.3)。
关键数值与推荐
- 完全肾脏缓解率伏环孢素组50.9% vs 对照组39.0%(OR 1.74;95%CI 1.00-3.03)。
- 两年eGFR斜率伏环孢素组-0.2 mL/min/1.73 m2(95%CI -3.0至2.7) vs 对照组-5.4 mL/min/1.73 m2(95%CI -8.4至-2.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: AURORA 2 evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one-year AURORA 1 study. METHODS: Enrolled patients continued their double-blinded treatment of voclosporin or placebo randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low-dose glucocorticoids. The primary objective was safety assessed with adverse events (AEs) and biochemical and hematological assessments. Efficacy was measured by renal response. RESULTS: A total of 216 patients enrolled in AURORA 2. Treatment was well tolerated with 86.1% completing the study and no unexpected safety signals. AEs occurred in 86% and 80% of patients in the voclosporin and control groups, respectively, with an AE profile similar to that seen in AURORA 1, albeit with reduced frequency. Investigator reported AEs of both glomerular filtration rate (GFR) decrease and hypertension occurred more frequently in the voclosporin than the control group (10.3% vs 5.0%, and 8.6% vs 7.0%, respectively). Mean corrected estimated GFR (eGFR) was within the normal range and stable in both treatment groups. eGFR slope over the two-year period was -0.2 mL/min/1.73 m2 (95% confidence interval [CI] -3.0 to 2.7) in the voclosporin group and -5.4 mL/min/1.73 m2 (95% CI -8.4 to -2.3) in the control group. Improved proteinuria persisted across three years of treatment, leading to more frequent complete renal responses in patients treated with voclosporin (50.9% vs 39.0%; odds ratio 1.74; 95% CI 1.00-3.03). CONCLUSION: Data demonstrate the safety and efficacy of long-term voclosporin treatment over three years of follow-up in patients with LN.
引用
- Saxena A, Ginzler EM, Gibson K, et al. Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis Rheumatol. 2023. PMID: 37466424. doi:10.1002/art.42657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。